Table 2.
Bone turnover marker | BMD | Fracture risk | ||
---|---|---|---|---|
Bone formation | Bone resorption | |||
Metformin | ↓/∼ | ↓/∼ | ∼/↑ | ↓/∼ |
Sulfonylureas | ↑/∼ | ↓/∼ | ND | ↓/∼/↑ |
Thiazolidinediones | ↓↓/∼/↑ | ↑↑/∼ | ↓↓/∼ | ↑↑ |
GLP-1 analogues | ∼ | ↓↓ | ↑/∼ | ∼ |
DPP4 inhibitors | ↓/∼ | ∼ | ∼ | ∼/↓ |
SGLT2 inhibitors | ∼ | ∼/↑ | ∼ | ∼/↑ |
Insulin | ∼ | ∼ | ∼ | ↑ |
Abbreviations: ↑∣increased; ↓∣decreased; ∼∣unchanged; BMD, bone mineral density; DPP4, dipeptidyl peptidase inhibitor 4; GLP1, glucagon-like peptide 1; ND, not determined; SGLT2, sodium/glucose cotransporter 2.